COMPARATIVE CHARACTERISTIC OF DIFFERENT IMMUNOMODULATOR INTRODUCTION WAYS FOR PREVENTION OF PYOSEPTIC PANCREONECROTIC COMPLICATIONS

Aim. To prove the efficiency of using immunomodulator “Derinat” for patients with aseptic pancreatonecrosis and to compare the efficiency of rectal and intramuscular ways of drug introduction. Materials and methods. The group of comparison consisting of 30 patients diagnosed aseptic pancreatonecrosis received standard therapy; 30 patients of subgroup I of the main group received standard therapy and rectal introduction of immunomodulator; 30 patients of subgroup II received standard therapy and intramuscular introduction of immunomodulator. Immunomodulator “Derinat” raised the percentage ratio of T-lymphocytes, T-helpers, B-lymphocytes, phagocytes in patients of the main group versus the comparison group. Results. The lactulose/mannitol test indices in patients of subgroup I were significantly lower than those in subgroup II and the comparison group. Intramuscular and rectal use of immunomodulator “Derinat” reduced the number of complications: 53,3 ± 5,6 % in subgroup I and 62,7 ± 6,7 % in subgroup II versus the comparison group - 64,0 % ± 17,4 %. The number of operative interventions decreased: 50,0 ± 8,9 % and 49,9 ± 5,4 % in patients of subgroups I and II, respectively, versus the comparison group. Lethality was 13,3 ± 3,5 % and 16,7 ± 4,2 % in patients of subgroups I and II, respectively, in comparison group - 20,0 ± 3,4 %. Conclusions. Application of immunomodulator “Derinat” for prevention of pyoseptic complications is confirmed; maximum effect is reached with rectal introduction of the drug.

Aseptic pancreatonecrosis, immunomodulator, pyoseptic pancreonecrotic complications